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CLINICAL OBSERVATIONS, INTERVENTIONS,AND THERAPEUTIC TRIALS
Prognostic signiﬁcance of activating FLT3 mutations in younger adults
(16 to 60 years) with acute myeloid leukemia and normal cytogenetics:
a study of theAMLStudy Group Ulm
Stefan Fro ¨hling, Richard F. Schlenk, Jochen Breitruck, Axel Benner, Sylvia Kreitmeier, Karen Tobis, Hartmut Do ¨hner, and Konstanze Do ¨hner
To assess the prognostic relevance of
activating mutations of the FLT3 gene in
homogeneously treated adults 16 to 60
years of age with acute myeloid leukemia
(AML) and normal cytogenetics, pretreat-
ment samples from 224 patients entered
into 2 consecutive multicenter treatment
trials were analyzed for FLT3 internal tan-
dem duplications (ITDs) and Asp835 mu-
tations. Treatment included intensive
double-induction therapy and postremis-
sion therapy with high cumulative doses
of high-dose cytarabine. ITDs were de-
tected in 32% of the patients and were
related to de novo AML and to high white
blood cell (WBC) counts, percentages of
peripheral blood (PB) and bone marrow
(BM)blasts,andserumlactatedehydroge-
nase levels. Asp835 mutations were
present in 14% of the patients and were
associatedwithWBCcountsandpercent-
ages of PB and BM blasts that were
higherthanthoseofpatientswithoutFLT3
mutations. With a median follow-up of 34
months, remission duration and overall
survival (OS) were signiﬁcantly shorter
for patients with Asp835 mutations or an
ITD than for those without FLT3 muta-
tions (P  .03 and P  .0004, respec-
tively). These results were attributable
mainly to the negative prognostic effect
of FLT3 ITDs. On multivariate analysis,
mutant FLT3 was an independent marker
affecting remission duration and OS (haz-
ard ratio, 2.35 and 2.11, respectively).
Fluorescence in situ hybridization did not
detect monoallelic FLT3 deletions in ITD-
positive patients. FLT3 mutations identify
a subset of young AML patients with
normal cytogenetics who do not beneﬁt
from intensive chemotherapy, including
double-induction and postremission
therapywithhigh-dosecytarabine.(Blood.
2002;100:4372-4380)
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Introduction
Karyotype is widely recognized as one of the most important
prognostic factors in acute myeloid leukemia (AML), and cytoge-
netic data are increasingly used to assign patients to distinct
prognostic groups in the context of modern risk-adapted treatment
protocols.1-4 By conventional chromosome-banding analysis, ap-
proximately 35% to 50% of successfully karyotyped patients lack
clonalchromosomeaberrations,4andnormalcytogeneticsisassoci-
ated with an intermediate clinical outcome.1,3,5 However, several
studies indicate thatAMLpatients with normal karyotypes molecu-
larly represent a heterogeneous group and that molecular differ-
ences are likely to correlate with prognosis.6-8 Therefore, the
identiﬁcation of new molecular markers and their prospective
validation within multicenter treatment trials is critical.
FMS-like tyrosine kinase 3 (FLT3), a member of the class 3
receptor tyrosine kinase (RTK) family, is preferentially expressed
on hematopoietic progenitor cells and mediates stem cell differen-
tiation and proliferation.9,10 Interaction of FLT3 with its natural
ligand results in activation of the receptor through dimerization and
subsequent autophosphorylation of FLT3 proteins,11 followed by
induction of multiple intracellular signaling pathways.12 Similarly,
ligand-induced FLT3 activation has been shown to enhance the
proliferative capacity ofAMLcells in vitro.13
Like other class 3 RTKs (eg, FMS, KIT, PDGF), FLT3 consists
of 5 extracellular immunoglobulinlike domains—a transmembrane
domain, a juxtamembrane (JM) domain, 2 intracellular tyrosine
kinase (TK) domains separated by a kinase insert domain, and an
intracellular C-terminal domain.14 The gene encoding FLT3 maps
to chromosome band 13q12 and comprises 24 exons that span a
genomic region of approximately 100 kb.15,16
Two types of activating FLT3 mutations have been described in
AML. An internal tandem duplication (ITD) of the FLT3 gene
(FLT3 ITD) can be detected in 20% to 30% of younger adults with
AML.17-24 The duplication involves a segment of the JM domain–
coding sequence (exons 14 and 15) in direct head-to-tail orientation
and is always in-frame.20,21,24,25 In vitro, FLT3 ITDs cause ligand-
independent receptor dimerization and constitutive activation of
the TK domains, leading to constitutive activation of signaling
through the RAS, mitogen-activated protein kinase (MAPK), and
signal transducer and activator of transcription 5 (STAT5) path-
ways. Supporting a potential role in leukemogenesis, FLT3 ITDs
from AML patients have been shown to induce autonomous
proliferation in cytokine-dependent cell lines.26-29 Point mutations
of Asp835 (3-letter amino acid code) within the FLT3 TK domain
have recently been described in 7% of adultAMLpatients.30,31 Like
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of the receptor and induce autonomous proliferation of 32D cells.31
Of note is that FLT3 Asp835 mutations appear to occur indepen-
dently of FLT3 ITDs.
Previous studies have suggested that FLT3 ITD is associated
with signiﬁcantly worse clinical outcomes in younger adults17-19,21
and in pediatric patients25,32 with AML. However, studies showing
an association of this mutation with poor outcome in adult AML
were limited by the fact that patient populations were highly
heterogeneous with regard to age at diagnosis, karyotype, and
treatment regimens. In particular, none of these studies speciﬁcally
looked at the subgroup of patients with normal cytogenetics. In a
recent study, investigators of the Cancer and Leukemia Group B
(CALGB) examined diagnostic bone marrow (BM) samples for
FLT3 ITD in 82 adults younger than 60 years of age with de novo
AMLand normal cytogenetics who had been treated within a single
multicenter treatment trial. Within this homogeneous patient popu-
lation, the mere presence of a FLT3 ITD was not associated with
inferior clinical outcome.23 Another important aspect of this study
was the identiﬁcation of 8 FLT3 ITD–positive patients who lacked
DNA polymerase chain reaction (PCR) evidence of an FLT3
wild-type allele. Multivariate analysis showed that this genotype
was the only signiﬁcant prognostic marker predicting for disease-
free survival (DFS) and overall survival (OS). The presence of a
FLT3 Asp835 mutation did not provide independent prognostic
information in the 2 studies published to date.30,31
In this study, we aimed to evaluate the prognostic relevance of
activating FLT3 mutations in adult AML patients entered into the
GermanmulticentertreatmenttrialsAMLHD93andAMLHD98-A
of the AML Study Group Ulm (AMLSG ULM). Our primary
objective was to determine whether the presence of a FLT3 ITD or
a FLT3 Asp835 mutation deﬁnes a group with poor prognosis
within the heterogeneous group of AML patients with normal
cytogenetics. Furthermore, we used ﬂuorescence in situ hybridiza-
tion (FISH) for the detection of monoallelic FLT3 deletions in
FLT3 ITD–positive patients.
Patients, materials, and methods
Patients
Diagnostic BM or peripheral blood (PB) samples were available from 523
adult patients (aged 16 to 60 years) with AML diagnosed according to
French-American-British Cooperative Group criteria33 who had been
entered into the German multicenter treatment trials AML HD93 (185
patients; August 1993 to January 1998) and AML HD98-A (338 patients;
February 1998 to November 2001). AML HD93 enrolled patients with de
novo AML and patients with secondary AML following treatment of a
primary malignancy (t-AML). The ongoing AML HD98-A trial also
includes patients with refractory anemia with excess blasts in transforma-
tion (RAEB-t) and patients withAMLfollowing myelodysplastic syndrome
(s-AML). Of the 523 patients, 447 (85%) had de novo AML, 37 (7%) had
s-AML, 19 (4%) had t-AML, and 20 (4%) had RAEB-t. For this molecular
study, the only criterion used to include or exclude patients was the
availability of BM or PB samples from diagnosis for mutation analysis of
the FLT3 gene. All patients gave informed consent for treatment and
cryopreservation of BM and PB. The study was approved by the institu-
tional review boards of the participating AMLSG ULM institutions (see
“Appendix”). Informed consent was provided according to the Declaration
of Helsinki.
Therapy of patients with normal cytogenetics
All patients entered into the AML HD93 and AML HD98-A trials received
intensive,response-adapteddouble-inductionandconsolidationtherapy.Double-
induction therapy consisted of a course of ICE (12 mg/m2 idarubicin on days 1
through 3; 100 mg/m2 cytarabine continuously on days 1 through 7; 100 mg/m2
etoposide on days 1 through 3), followed by a second course of ICE started
betweendays21and28inpatientswitharesponsetotheﬁrstcourseofinduction
therapy, or by a course of a HAM-based (3 g/m2 cytarabine every 12 hours on
days 1 through 3; 12 mg/m2 mitoxantrone on days 2 and 3) regimen in patients
with ICE-refractory disease. First consolidation therapy consisted of a course
of HAM.
Second consolidation therapy differed between the 2 trials. In theAML
HD93 trial, patients 16 to 54 years of age were assigned to receive a course
according to the S-HAM protocol (3 g/m2 cytarabine every 12 hours on
days 1, 2, 8, and 9; 10 mg/m2 mitoxantrone on days 3, 4, 10, and 11);
patients 55 to 60 years of age received the less intensive HAM regimen. In
theAMLHD98-Atrial, patients were randomized to receive either a second
course of HAM or myeloablative therapy (total body irradiation/
cyclophosphamide or busulfan/cyclophosphamide), followed by autolo-
gous stem cell transplantation (SCT). In both trials, patients were assigned
to undergo allogeneic SCT if an HLA-compatible donor was available.
Cytogenetic and molecular cytogenetic analysis
Pretreatment samples from all patients were studied centrally by G-banding
analysis and FISH. Conventional cytogenetic studies were performed using
standard techniques, and chromosomal abnormalities were described
according to the International System for Cytogenetic Nomenclature.34 To
improve the accuracy of cytogenetic diagnosis, all specimens were also
analyzed by FISH using a comprehensive DNA probe set allowing for the
detection of the most relevantAML-associated genomic aberrations.35,36 In
addition, diagnostic samples from all patients were analyzed for the
presence of a partial tandem duplication of the mixed lineage leukemia gene
(MLL PTD) by Southern blotting of genomic DNA.7 MLL PTD positivity
was conﬁrmed by PCR and sequencing of PCR products.
Analysis of FLT3 ITDs
Genomic DNA was isolated from mononuclear cell preparations stored at
70°C using the DNAzol reagent (Gibco BRL, Eggenstein, Germany)
according to the manufacturer’s recommendations. Because the location of
FLT3 ITDs is restricted to exons 14 and 15,15,18,24,37 PCR ampliﬁcation of
genomic DNA was carried out using primers 11F (5-GCAATT TAG GTA
TGAAAG CCAGC-3) and 12R (5-CTTTCAGCATTTTGACGG CAA
CC-3), described previously.18 The total reaction volume of 50 L
contained approximately 500 ng DNA and 10 pmol each primer. Samples
were ampliﬁed using standard PCR conditions (95°C for 7 minutes; 35
cycles of 95°C for 1 minute, 56°C for 1 minute, 72°C for 2 minutes; 72°C
for 10 minutes). PCR products were resolved on a 2% agarose gel stained
with ethidium bromide. Repeat analysis was carried out on a 2.5%
low-melting–point (LMP) agarose gel if loss of the FLT3 wild-type allele
was suspected.
In the 27 patients from the AML HD93 trial with an additional PCR
fragment, the ampliﬁed product was cloned into the pCR4-TOPO vector
(Invitrogen, Groningen, The Netherlands). Ten recombinant colonies were
chosen and cultured in Luria-Bertani medium. Plasmid DNA was prepared
using the Plasmid Mini Kit (Qiagen, Hilden, Germany). Sequencing was
performed using the ABI Ready Reaction Dye Terminator Cycle Sequenc-
ing Kit (Applied Biosystems, Weiterstadt, Germany) and the T3 primer on
anABI 310 Prism sequencer (Applied Biosystems).
Analysis of FLT3 Asp835 mutations
Exon 20 of the FLT3 gene was ampliﬁed by genomic DNA PCR using
primers 20A (5-CCA GGAACG TGC TTG TCA-3) and E20IR (5-TCA
AAA ATG CAC CAC AGT GAG-3), as previously reported.30 Samples
were ampliﬁed using standard PCR conditions (95°C for 10 minutes; 35
cycles of 95°C for 1 minute, 56°C for 1 minute, 72°C for 1 minute; 72°C for
10 minutes). PCR products were digested with EcoRV and resolved on an
agarose gel, as described previously.30,31 Undigested bands, indicative of a
FLT3Asp835 mutation, were cut out for direct nucleotide sequencing using
primer 20Ato conﬁrm the presence of a FLT3Asp835 mutation.
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Sequence analysis using the basic local alignment search tool (BLAST)
program (http://www.ncbi.nlm.nih.gov/BLAST/) showed that nucleotides 3
to 2599 of the FLT3 cDNAsequence (GenBank accession no. NM_004119)
are contained within bacterial artiﬁcial chromosome (BAC) clones RP11-
179F17 (GenBank accession no. AL356915) and RP11-9D14 (GenBank
accession no. AL445262). These clones were used as probes for the
detection of monoallelic deletions of the FLT3 gene in patients with a FLT3
ITD. Dual-color FISH was performed as described.35,36
Criteria for treatment outcomes
Response to induction therapy was assessed at 2 different time points. The
ﬁrst time point was between days 21 and 28 after the ﬁrst course of
induction therapy. Response to the ﬁrst course of induction therapy was
deﬁned as a 50% or greater reduction of BM blasts from pretreatment
values. Because the second course of induction therapy was scheduled to
start immediately after assessment of the response to the ﬁrst course of
induction therapy, complete hematologic reconstitution was not a require-
ment. The second time point for assessment of response was after
double-induction therapy. In accordance with standard criteria,38 complete
remission (CR) required less than 5% BM blasts, an absolute neutrophil
count of 1.5  109/L or more, a platelet count of 100  109/L or more, no
blasts in the PB, and no extramedullary leukemia. Therapeutic failure was
classiﬁed as refractory disease or early/hypoplastic death (death less than 7
days after completion of the ﬁrst course of induction therapy/death during
the remainder of double-induction therapy). Relapse was deﬁned as more
than 10% blasts in 2 BM aspirates obtained within 2 weeks or new
extramedullary leukemia in patients with previously documented CR.
Remission duration end points measured from the date of documented CR
were relapse (failure), death in CR (censored), and alive in CR at last
follow-up (censored). Overall survival end points measured from the date
of study entry were death (failure) and alive at last follow-up (censored).
Statistical analyses
Analyses were based on data available as of November 30, 2001. The
median follow-up duration was calculated according to the method of
Korn.39 Clinical features were compared across these 3 groups: patients
without FLT3 mutation, patients with FLT3 Asp835 mutation, and patients
with FLT3 ITD. Binary variables were compared using Fisher exact test.
Continuous variables were compared using the Kruskal-Wallis test. For
variables reporting signiﬁcance at P  .05 level, pairwise comparisons
were conducted. Pairwise comparisons of binary variables were conducted
using Fisher exact test. Pairwise comparisons of continuous variables were
conducted using the Wilcoxon rank-sum test. To assess the signiﬁcance of
pairwise comparisons, the  level was adjusted to 0.05  3  0.0167.
The Kaplan-Meier method was used to estimate distributions of remission
duration and OS.40 Differences between Kaplan-Meier curves were ana-
lyzed using the log-rank test.41 The Cox proportional hazards regression
model was used to identify differences in remission duration and OS due to
prognostic factors.42 As possible prognostic factors, FLT3 mutation status
(FLT3 Asp835 mutation or FLT3 ITD), a 10-year increment in age, an
increment of 50  109/L in the diagnostic white blood cell (WBC) count,
serum lactate dehydrogenase (LDH) level, MLL PTD status, and response
to the ﬁrst course of induction therapy (for remission duration) were
included in the regression model. The variable “study” (AML HD93 or
AML HD98-A) was incorporated as a stratiﬁcation factor to account for
study effects on remission duration and OS. Statistical computations were
performed using the statistical software packages SAS 6.12 (SAS Institute,
Cary, NC) and StatXact (Cytel Software, Cambridge, MA).
Results
Prevalence of FLT3 ITDs in adult AML
The incidence of FLT3 ITDs was determined in all 523 patients
with an adequate pretreatment sample: in 27 patients with t(8;21),
in 43 patients with inv(16), in 51 patients with t(15;17), in 224
patients with normal karyotypes, in 29 patients with t(11q23), in 45
patients with complex karyotypes (deﬁned as the presence of 3 or
more clonal aberrations other than the above balanced transloca-
tions), in 78 patients with other chromosome abnormalities, and in
26 patients without evaluable karyotype.
FLT3 ITD was identiﬁed in 119 of the 523 (23%) patients. The
frequency of FLT3 ITDs differed signiﬁcantly between cytogenetic
groups (P  .0001): of the 224 patients with normal karyotypes, 71
(32%) wereFLT3 ITD–positive; of the 51 patients with t(15;17), 20
(39%) exhibited the mutation. In contrast, FLT3 ITDs were rarely
observed in patients with t(8;21) (3 of 27 patients; 11%), inv(16) (1
of 43 patients; 2%), or t(11q23) (2 of 29 patients; 7%). Only 1 of
the 45 (2%) patients with complex karyotypes was FLT3 ITD–
positive. Of the 78 patients with other chromosome abnormalities,
13 (17%) were FLT3 ITD–positive. Four of these 13 patients had
trisomy 8 as the sole cytogenetic abnormality. The remaining 9
patients had the following chromosome aberrations: Y; t(3;8)
(q13.2;q24.1);t(6;9)(p23;q34);der(7)t(7;13)(q32;q12),13;t(9;15)
(q22;q22); add(10)(q26); t(11;15)(p15;q11), t(12;20)(q21;?q12?3);
t(11;20)(p15;q11); 	20.
There was also a signiﬁcant difference in the frequency of FLT3
ITDs between patients with de novo AML (114 of 447 patients;
26%) and secondaryAML—that is, s-AML, t-AML, or RAEB-t (7
of 76 patients; 9%; P  .001).
Sequencing analysis of the 27 FLT3 ITD–positive patients with
normal cytogenetics from theAML HD93 trial showed FLT3 ITDs
varying in length from 18 to 122 base pairs (median, 36).
Twenty-three patients had simple FLT3 ITDs within exon 14, and 4
patients had FLT3 ITDs involving exon 14 and intron 14. Insertions
of 1 to 9 nucleotides (median, 2) of unknown origin between the
duplicatedregionswereobservedin8patients.Asaresult,allFLT3
ITDs were readable in-frame.
Prevalence of FLT3 Asp835 mutations in adult AML
with normal cytogenetics
The incidence of FLT3 Asp835 mutations was determined in the
224 patients with normal cytogenetics. FLT3 Asp835 mutations
were identiﬁed in 32 (14%) patients. Sequencing analysis showed 5
kindsofheterozygousFLT3Asp835missensemutations:Asp835Tyr
(17 patients), Asp835Glu (6 patients), Asp835Val (3 patients),
Asp835His (2 patients), and Asp835Ala (1 patient). In 2 patients,
sequencing analysis revealed a 1–base pair deletion of Ile836 and a
2–base pair deletion of Met837 (nucleotides 2565 to 2567 of the
FLT3 cDNA sequence [GenBank accession no. NM_004119]),
resulting in an in-frame deletion of Ile836. One patient had both a
2560G
T transversion, resulting in an Asp835Tyr missense muta-
tion, and a deletion of nucleotides 2565 to 2567. In 1 of the 32
patients with mutations, the presence of an FLT3Asp835 mutation
could not be conﬁrmed because no material was available for
sequencing analysis. Four of the 32 (13%) patients with FLT3
Asp835 mutations also had a FLT3 ITD.
Analysis of monoallelic FLT3 deletions
Considerable differences in the intensity of the mutant band were
observed in patients with FLT3 ITD (Figure 1). Some patients
showed strong mutant bands and only faint wild-type bands. On
LMP gel electrophoresis, only 1 of the 224 (0.4%) patients with
normal cytogenetics displayed a strong mutant band and complete
loss of the wild-type allele. Thus, the incidence of loss of the
wild-type allele in our study was considerably lower than that
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in the latter study only BM samples had been analyzed raised the
possibility that the 0.4% value found in our study was an
underestimate because the higher proportion of residual normal
cells in PB samples would tend to decrease the ratio of the mutant
to wild-type FLT3 allele. To investigate whether the frequency of
loss of the wild-type allele is related to the material analyzed (BM
or PB), we studied diagnostic BM and PB samples from 5 FLT3
ITD–positive patients. Although the percentages of PB blast cells
were lower in 4 of 5 patients (68% vs 90%; 73% vs 99%; 32% vs
unknown; 6% vs 60%; 64% vs 90%), BM and PB samples were
indistinguishable on LMPgel electrophoresis (Figure 2).
To test the hypothesis that some FLT3 ITDs are associated with
monoallelic FLT3 deletions, all 27 FLT3 ITD–positive patients
with normal cytogenetics from the AML HD93 trial, including the
patient with complete loss of the wild-type allele, and 4 additional
FLT3 ITD–positive patients with normal cytogenetics from the
AML HD98-A trial were studied using FISH with BAC clones
RP11-179F17 and RP11-9D14. In all 31 patients, at least 95% of
interphase nuclei exhibited 2 strong ﬂuorescence signals with both
clones, indicating that no FLT3 allelic deletion had occurred in
these patients (Figure 3).
Baseline characteristics of patients with normal cytogenetics
Clinical features of the patients with normal cytogenetics were
analyzed comparing the following 3 groups (Table 1): patients
without FLT3 mutation, patients with FLT3 Asp835 mutation,
and patients with FLT3 ITD. The 4 patients who had both
mutations were excluded from this analysis. As noted earlier,
comparisons across the 3 groups were followed by relevant
pairwise comparisons. Secondary AML was signiﬁcantly less
frequent in patients with FLT3 mutations (P  .002 for the
comparison across the 3 groups): only 1 of the 28 (4%) patients
with a FLT3Asp835 mutation and only 2 of the 67 (3%) patients
with FLT3 ITD had s-AML, t-AML, or RAEB-t. Median WBC
counts increased from 12.5  109/L in patients without FLT3
mutation to 24.8  109/L in patients with FLT3 Asp835 muta-
tion and were highest in patients with FLT3 ITD (44.8  109/L;
P  .0002 for comparison across the 3 groups). Pairwise
comparisons showed that the difference between patients with-
out FLT3 mutations and patients with FLT3 ITD was statisti-
cally signiﬁcant (P  .0001). In contrast, there were no differ-
ences between patients without FLT3 mutations and patients
with FLT3Asp835 mutations (P  .11) or between patients with
FLT3 Asp835 mutations and patients with FLT3 ITD (P  .13).
Percentages of PB blasts increased from 35% in patients without
FLT3 mutations to 43% in patients with FLT3Asp835 mutations
and were highest in patients with a FLT3 ITD (65%; P  .001
for comparison across the 3 groups). Pairwise comparisons
showed that the differences between patients without FLT3
mutations and patients with a FLT3 ITD and between patients
with a FLT3 Asp835 mutation and patients with a FLT3 ITD
were statistically signiﬁcant (P  .0005 and P  .01, respec-
tively). In contrast, there was no difference between patients
without FLT3 mutations and patients with FLT3 Asp835 muta-
tions (P  .61). Percentages of BM blasts were signiﬁcantly
higher in patients with FLT3 mutations (FLT3Asp835 mutation,
90%; FLT3 ITD, 90%) than in patients without FLT3 mutations
(76%; P  .0002 for comparison across the 3 groups). Serum
LDH levels were signiﬁcantly higher in FLT3 ITD–positive
patients (643 U/L) than in patients with FLT3Asp835 mutations
(372 U/L) and in patients without FLT3 mutations (420
U/L; P  .0005 for comparison across the 3 groups).There were
no signiﬁcant differences with respect to other clinical character-
istics such as sex, age, hemoglobin level, platelet count,
lymphadenopathy, or other extramedullary involvement among
the 3 groups. Similar frequencies of MLL PTD-positive patients
were found in patients without FLT3 mutations, patients with
FLT3 Asp835 mutations, and patients with FLT3 ITD (6%, 8%,
and 9%, respectively; P  .64 for comparison across the
3 groups).
Figure 1. Detection of FLT3 ITD in younger adults with AML. Exons 14 and 15 of
the FLT3 gene were PCR ampliﬁed from genomic DNA, and PCR products were
resolved on a 2% agarose gel stained with ethidium bromide. Arrow indicates the
normal FLT3 gene product (328 bp). High-molecular–weight bands represent FLT3
ITDs. Sample 1 shows a strong mutant band and loss of the wild-type allele.
M indicates 100-base pair DNA ladder (Gibco BRL); 1-12, samples from 12 different
AMLpatients.
Figure 2. Comparison of BM and PB samples from FLT3 ITD–positive patients.
Exons 14 and 15 of the FLT3 gene were PCR ampliﬁed from diagnostic BM and PB
specimens from 5 patients with FLT3 ITDs, and PCR products were resolved on a
2.5% LMP agarose gel. Percentages of BM and PB blast cells are shown below the
gel. Although the proportion of PB blast cells was considerably lower in 4 of 5
patients, BM and PB samples were indistinguishable on LMP gel electrophoresis.
WT indicates samples from a patient without FLT3 ITD; 1-5, samples from 5 different
AMLpatients with FLT3 ITDs; and ?, the percentage of BM blasts was unknown in the
patient.
Figure 3. Analysis of monoallelic FLT3 deletions. Interphase nuclei from the
patient with loss of the wild-type allele were studied by FISH using BAC clone
RP11-179F17 (green). Cohybridization with a probe recognizing a genomic region at
chromosome band 7q35 (red) was performed to monitor hybridization efﬁciency.All 7
nuclei exhibit 2 green and 2 red ﬂuorescence signals, indicating that no monoallelic
FLT3 deletion occurred in this patient. Identical results were obtained with BAC clone
RP11-9D14 (not shown). Original magniﬁcation  100.
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with normal cytogenetics
There was no signiﬁcant difference in response to double-induction
therapy between patients without FLT3 mutations, patients with
FLT3 Asp835 mutations, and patients with FLT3 ITD (P  .27 for
comparison across the 3 groups): 76% of the patients without FLT3
mutations, 82% of the patients with FLT3 Asp835 mutations, and
65% of the FLT3 ITD–positive patients achieved CR.
Remission duration and survival of patients
with normal cytogenetics
With a median follow-up of 34 months, FLT3 mutation status
strongly predicted for remission duration and survival of the
patients with normal cytogenetics. Median remission duration was
signiﬁcantly shorter for patients with FLT3 mutations (FLT3
Asp835 mutation, FLT3 ITD, or both) than for those without FLT3
mutations (P  .03 for comparison across the 3 groups; Figure 4).
Pairwise comparisons showed that the difference in remission
duration between patients without FLT3 mutations and patients
with FLT3 ITD was statistically signiﬁcant (P  .007). In contrast,
there were no differences in remission duration between patients
without FLT3 mutations and patients with FLT3Asp835 mutations
(P  .18) and between patients with FLT3 Asp835 mutations and
patients with FLT3 ITD (P  .42). Median OS was also signiﬁ-
cantly shorter for patients with FLT3 mutations (FLT3 Asp835
mutation, FLT3 ITD, or both) than for those without FLT3
mutations (P  .0004 for comparison across the 3 groups; Figure
5). Pairwise comparisons showed that the difference in OS between
patients without FLT3 mutations and patients with FLT3 ITD was
statistically signiﬁcant (P  .0001). In contrast, there were no
differences in OS between patients without FLT3 mutations and
patients with FLT3 Asp835 mutations (P  .63) and between
patients with FLT3 Asp835 mutations and patients with FLT3 ITD
(P  .03).
Cox regression analysis identiﬁed response to the ﬁrst course of
inductiontherapy(hazardratio,5.45[95%conﬁdenceinterval(CI),
2.26-13.15]), MLL PTD (hazard ratio, 4.47 [95% CI, 2.19-9.11]),
and presence of a FLT3 mutation (hazard ratio, 2.35 [95% CI,
1.34-4.12]) as the most signiﬁcant prognostic factors for remission
duration (Table 2). The strongest prognostic markers for OS were
presence of a FLT3 mutation (hazard ratio, 2.11 [95% CI,
1.39-3.21]), WBC count (hazard ratio, 1.36 [95% CI, 1.16-1.59]),
and age (hazard ratio, 1.29 [95% CI, 1.04-1.60]). There was also a
Table 1. Characteristics of 220 patients with normal cytogenetics according to FLT3 mutation status
No FLT3 mutation,
n  125
FLT3 Asp835 mutation,
n  8
FLT3 ITD,
n  67 P
Male sex, % 51 43 36 .12
Median age, y 47 47 47 .71
Range 16-60 16-60 19-60
Secondary disease status, % 18 4 3 .002
Median Hb level, g/dL 8.9 9.1 8.9 .95
Range 4.8-8.8 4.1-14.9 5.3-13.2
Median platelets, 109/L 53 70 62 .12
Range 5-746 11-361 12-248
Median WBC count, 109/L 12.5 24.8 44.8 .0002
Range 0.2-369 2.2-202 0.7-345
Median PB blasts, % 35 43 65 .001
Range 9-99 0-89 2-100
Median BM blasts, % 76 90 90 .0002
Range 0-100 28-90 9-100
Median LDH, U/L 420 372 643 .0005
Range 89-1871 176-1650 122-4091
Lymphadenopathy, % 22 (n  117) 22 (n  27) 22 (n  65) 1.0
Extramedullary involvement, % 9 (n  117) 11 (n  27) 9 (n  64) .88
MLL PTD, % 6 (n  121) 8 9 (n  66) .64
Hb indicates hemoglobin.
Figure 4. Remission. Remission duration for patients with normal cytogenetics
according to FLT3 mutation status.
Figure 5. Overall survival. Overall survival for patients with normal cytogenetics
according to FLT3 mutation status.
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induction therapy and OS (P  .0001).
Discussion
We determined the prognostic signiﬁcance of activating FLT3
mutations (ITDs and Asp835 mutations) in a large prospective
series of more than 200 young adults with AML and normal
cytogenetics. FLT3 ITDs were detected in 32% of the patients and
were related to de novo AML and to high WBC counts, high
percentages of PB and BM blasts, and elevated serum LDH levels.
FLT3 Asp835 mutations were present in 14% of our patients and
were also associated with WBC counts and percentages of PB and
BM blasts that were higher than those of patients without FLT3
mutations. On multivariate analysis, FLT3 mutation status was
found to have a major impact on remission duration and OS, which
was attributable mainly to the negative prognostic effect of
FLT3 ITDs.
Four previous studies have suggested that the presence of FLT3
ITD is associated with poor outcomes in younger adults with
AML.17-19,21 However, these data were obtained in patient popula-
tions that were highly heterogeneous with regard to age at
diagnosis, karyotype, and treatment regimens. In contrast, our
patients were homogeneous with respect to age (younger adults; 16
to 60 years) and treatment (double-induction therapy, followed by
intensive consolidation therapy based on signiﬁcant cumulative
doses of high-dose cytarabine). Furthermore, we speciﬁcally
looked at the subgroup of patients with normal cytogenetics.
The results from our study allow assessment of the impact of
FLT3 mutations on the outcome of patients receiving consolidation
therapy with high-dose cytarabine, which is considered the best
conventional treatment option available for patients up to the age of
60 years. The patients reported by Kiyoi et al18 were treated
according to theAML-87,43AML-89,44 andAML-9245 protocols of
the JapanAdult Leukemia Study Group.Within these protocols, the
maximum dose of cytarabine per course of postremission therapy
was 200 mg/m2 for 5 days as continuous infusion. Furthermore,
patients received behenoyl cytarabine instead of cytarabine during
postremission therapy or were randomized between these 2 drugs.
Patients included in the survival analysis by Rombouts et al21 were
treated according to the HOVON-29,46 HOVON-4,47 and
HOVON-31 protocols of the Dutch-Belgian Hemato-Oncology
Cooperative Group (HOVON), the Swiss Group for Clinical
Cancer Research (SAKK), and the AML-11 protocol of the
HOVON and EORTC-LCG (European Organisation for the Re-
search and Treatment of Cancer Leukemia Cooperative Group)
groups.48 HOVON-31 and AML-11 were designed for elderly
patientsanddidnotincludehigh-dosecytarabine.IntheHOVON-29
and HOVON-4 trials, patients in CR received further chemo-
therapy with mitoxantrone and etoposide or underwent autologous
or allogeneic SCT. Finally, patients reported by Abu-Duhier et al17
and Kottaridis et al19 had been entered into the recent United
Kingdom Medical Research Council (MRC) trials.49 In the MRC
AML 10 trial, ﬁrst consolidation therapy consisted of amsacrine,
cytarabine (200 mg/m2 for 5 days as continuous infusion), and
etoposide (MACE), followed by a second course of consolidation
chemotherapy with mitoxantrone and intermediate-dose cytarabine
(5 g/m2). For additional treatment, patients were randomized to
allogeneic SCT, autologous SCT, or observation. The currentAML
12 trial uses ﬁrst consolidation therapy with MACE in a similar
fashion. Further risk-adapted therapy includes autologous/alloge-
neic SCT and chemotherapy; the maximum dose of cytarabine
administered per cycle is 6 g/m2. In summary, none of these trials
used postremission therapy with cytarabine at a dose level of more
than 1 g/m2. As a consequence, cumulative doses of cytarabine
were signiﬁcantly lower than those administered within the AML
HD93 and AML HD98-A trials (Table 3). Intensive consolidation
chemotherapy using high-dose cytarabine has been shown to
signiﬁcantly improve DFS and OS of younger adults with AML.50
The effect of cytarabine dose on long-term remission is most
marked in patients with t(8;21) or inv(16) and then in patients with
normal cytogenetics.1 However, our data suggest that the negative
prognostic impact of FLT3 ITDs in patients with normal cytogenet-
ics cannot be overcome by intensive postremission therapy with
high-dose cytarabine. These ﬁndings contrast the results obtained
in a smaller cohort of younger adults with normal cytogenetics who
had been entered into a recent treatment trial of the CALGB
(CALGB 9621).23 Within this protocol, patients in CR received
postremission therapy with cytarabine at a dose level of 2 g/m2,
resulting in cumulative doses of cytarabine between 16 and 48
g/m2.51 As noted earlier, CALGB 9621 is the only study published
to date in which the mere presence of FLT3 ITD was not associated
with inferior clinical outcome.23
Another way of intensifying antileukemic treatment that has
been demonstrated to result in superior DFS of patients with AML
is double-induction therapy.52 Of the 9 protocols described above, 4
(HOVON-29, HOVON-4, MRC AML 10, and MRC AML 12)
administered 2 courses of induction therapy. In the HOVON trials,
the second induction course was scheduled to start within 6 weeks
of the ﬁrst course. In the MRC trials, the second course was
administered after a BM sample of adequate cellularity for the
assessment of remission status was obtained 18 to 21 days after the
end of the ﬁrst induction course. If the marrow was hypoplastic and
assessment of status was not possible, the second course was
postponed for another 7 to 10 days. Patients entered into the AML
HD93 and AML HD98-A trials received intensive induction
treatment consisting of 2 courses of idarubicin and standard-dose
cytarabine and etoposide (ICE). Thus, the results from previous
studies and our own data indicate that the inferior outcome
associated with FLT3 ITDs cannot be overcome by double-
induction therapy. Because the timing of induction therapy may be
critical, in particular with regard to the effect of prognostic factors
on outcome, one may speculate that conventional double-induction
approaches do not provide enough dose intensity to overcome the
negative prognostic impact of FLT3 ITDs. Data from the French
ALFA9000 trial suggest that the negative prognostic value of FLT3
ITDs can be overcome by reinforced double-induction regimens
using mitoxantrone and etoposide on day 22 of a standard 3 	 7
course or on day 8 of a 3 	 3 course.53
In accord with our ﬁndings in younger adults, the presence of a
FLT3 ITD was an independent risk factor for poor outcome in 91
pediatric patients who had been treated according to a single
treatment protocol (Children’s Cancer Group-2891).25 This proto-
col included intensive double-induction and postremission therapy
with cytarabine at a dose level of 3 g/m2, resulting in a cumulative
Table 2. Results of Cox regression analysis of remission duration
Variable Hazard ratio for remission duration (95% CI)
Refractory to ICE I 5.45 (2.26-13.15)
MLL PTD 4.47 (2.19-9.11)
Mutant FLT3* 2.35 (1.34-4.12)
*FLT3Asp835 mutation, FLT3 ITD, or both.
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12 g/m2.54
Some FLT3 ITD–positive patients lack wild-type FLT3, and
loss of heterozygosity (LOH) for 6 microsatellite markers at
chromosome band 13q12 has been demonstrated in such patients.23
Based on these observations, it has been hypothesized that the
FLT3 ITD is associated with deletion of the second FLT3 allele. In
our study, the frequency of patients with normal cytogenetics with
FLT3 ITD who lacked PCR evidence of a FLT3 wild-type allele
was 0.4%. This contrasts the data from the CALGB study23 in
which the incidence of FLT3 ITD positivity with loss of the FLT3
wild-type allele was 10%. It is possible that this difference is
related to the method used to visualize PCR ampliﬁcation products.
In the CALGB study, ampliﬁed products were electrophoresed
through conventional agarose gels. In our study, repeat analysis on
a 2.5% LMPagarose gel revealed a wild-type band in all but one of
the patients in whom loss of the FLT3 wild-type allele initially had
been suspected. Considering that loss of the wild-type allele has
been reported to be associated with signiﬁcantly inferior clinical
outcome in FLT3 ITD–positive patients,23 it appears appropriate to
use quantitative approaches to assess the ratio of the mutant to the
wild-type FLT3 allele and to determine the prognostic value of this
mutation pattern.19,55Agarose gel electrophoresis can deﬁnitely not
be used to estimate the relative representation of the mutant and
wild-type alleles. Even samples with highly different blast percent-
ages—forexample,6%(PB)versus60%(BM)—wereindistinguish-
able by this technique.
FISH analysis using 2 BAC clones that represent approximately
75% of the FLT3 cDNA sequence failed to identify monoallelic
FLT3 deletions in 31 FLT3 ITD–positive patients, including the
patient with complete loss of the wild-type allele. Thus, other
mechanisms (mitotic nondisjunction, mitotic recombination, gene
conversion) resulting in homozygosity rather than hemizygosity56
must be considered to account for the LOH events observed in
patients with FLT3 ITD.
Based on the ﬁnding that FLT3 Asp835 mutations are gain-of-
function mutations that enhance the proliferative capacity of AML
cells in vitro to the same extent as FLT3 ITDs,31 it has been
speculated that FLT3 Asp835 mutations may also affect clinical
outcomes of younger adults with AML. In our study, remission
duration and OS were shorter for patients with a FLT3 Asp835
mutation than for those without a FLT3 mutation. However, the
differences did not reach statistical signiﬁcance. Considering that
FLT3Asp835 mutations are less frequent than FLT3 ITDs (14% vs
32%), it is possible that larger patient populations must be studied
to detect a signiﬁcant prognostic impact of FLT3 Asp835 mutations.
The discovery of activating FLT3 mutations in AML has
important implications for the management of younger adults with
this disease. First, assessment of the FLT3 mutation status in
patients with normal cytogenetics allows the identiﬁcation of a
subset of patients who do not beneﬁt from intensive chemotherapy,
including double-induction and postremission therapy with high-
dose cytarabine, and thus may contribute to the stratiﬁcation of
therapy within this heterogeneous subgroup of patients. Second,
the high frequency of activating FLT3 mutations may result in their
use as molecular targets for monitoring minimal residual disease.57
Finally, the perception that activating FLT3 mutations play an
important role in leukemogenesis has led to the development of
biologically targeted therapies with RTK inhibitors that are being
studied in phase 1 and 2 trials.58-60
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Table 3. Cytarabine doses administered to adult FLT3 ITD–positive patients during induction and postremission therapy
Study
Cytarabine dose
Comment Reference 80-200 mg/m2 1 g/m2 2 g/m2 3 g/m2
AML-87 0.8-1.6 g/m2*† —— — Double induction if no CR after ﬁrst course 43
3.8 g/m2†‡
12.24 g/m2†§
AML-89 0.32-0.96 g/m2*
or
—— — Double induction if no CR after ﬁrst course 44
0.8-2.4 g/m2*†
2.12 g/m2‡
or
3.8 g/m2†‡
6.12 g/m2†§
AML-92 2 g/m2*† —— — Postremission therapy not reported 45
HOVON-29 1.4 g/m2* 12 g/m2* —— — 46
HOVON-4 1.4 g/m2* 12 g/m2* —— — 47
AML-11 1.4-2.8 g/m2* —— — Double induction if PR after ﬁrst course 48
1.4 g/m2‡
1.92 g/m2§
MRC AML 10 3.6 g/m2* 5 g/m2‡ —— — 49
1 g/m2‡
MRC AML 12 7.2 g/m2* 6 g/m2‡ —— —
Good/standard risk 2 g/m2‡
CALGB 9621 0.7-1.4 g/m2* — 16-48 g/m2‡ —— 51
AML HD93/98-A 1.4 g/m2* —— 18-42 g/m2‡ — 2
PR indicates partial remission; and —, no treatment with cytarabine at the corresponding dose level (eg, 3 g/m2) has been administered.
*Induction therapy.
†Including behenoyl cytarabine instead of cytarabine.
‡Consolidation therapy.
§Maintenance therapy.
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